Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505063 · ClinicalTrials.gov registry record · Phase 2
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT00505063: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00505063 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 76 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505063, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.
Interventions
- BIOLOGICAL Immunization Schedule patients <7 years.
- BIOLOGICAL Immunization Schedule patients > or = to 7 years and <11 years of age
- BIOLOGICAL Immunization Schedule patients > or = to 11 years of age
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2007-07-10 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505063
The ClinicalTrials.gov registry entry for NCT00505063 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Immunization Schedule patients <7 years. is the first listed.
NCT00505063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505063 about?
NCT00505063 is a clinical study titled "Prospective Trial of Vaccine Responses in Childhood Cancer Survivors". This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study becaus...
What is the current status of trial NCT00505063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2007-07-10. Estimated completion is 2025-06-11.
What interventions are being tested in trial NCT00505063?
The interventions under investigation include: Immunization Schedule patients <7 years. (BIOLOGICAL), Immunization Schedule patients > or = to 7 years and <11 years of age (BIOLOGICAL), Immunization Schedule patients > or = to 11 years of age (BIOLOGICAL).
Who is sponsoring clinical trial NCT00505063?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.